Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.39 |
| ▸ | HTR2B | P41595 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | PNMT | P11086 | 3/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19678850 | 0.91 | PNMT (0.39) | ASIC3HTR2CHTR2BHTR2APNMT | |
| SCHEMBL19684606 | 0.91 | PNMT (0.39) | ASIC3HTR2CHTR2BHTR2APNMT | |
| SCHEMBL19678873 | 0.89 | PNMT (0.42) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL19406903 | 0.88 | PNMT (0.39) | ASIC3HTR2CHTR2BHTR2APNMT | |
| SCHEMBL19684605 | 0.84 | PNMT (0.39) | PNMTADRA2AADRA2BADRA2CHTR6 | |
| SCHEMBL19684578 | 0.82 | ASIC3 (0.43) | ASIC3HTR2CHTR2BHTR2APNMT | |
| SCHEMBL19684591 | 0.81 | PNMT (0.41) | HTR2CHTR2BHTR2APNMTADRA2A | |
| SCHEMBL19678848 | 0.79 | PNMT (0.42) | HTR2CHTR2APNMTADRA2AADRA2B | |
| SCHEMBL19678876 | 0.78 | PNMT (0.39) | HTR2CHTR2BHTR2APNMTPRMT5 | |
| SCHEMBL20778182 | 0.78 | PNMT (0.49) | ASIC3HTR2CHTR2BHTR2APNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | ASIC3 4751/4885HTR2C 4759/4885HTR2B 4558/4885 |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | ASIC3 4751/4885HTR2C 4759/4885HTR2B 4558/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | ASIC3 4751/4885HTR2C 4759/4885HTR2B 4558/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | ASIC3 4751/4885HTR2C 4759/4885HTR2B 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.